Ferrer, J.L.M.; Garcia, R.L. Antioxidant Systems, lncRNAs, and Tunneling Nanotubes in Cell Death Rescue from Cigarette Smoke Exposure. Cells 2022, 11, 2277. https://doi.org/10.3390/cells11152277

 

Garrido, J.A.M.G.; Alcantara, K.M.M.; Danac, J.M.C.; Serrano, F.E.C.; Cutiongco-de la Paz, E.M.; Garcia, R.L. The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene. Cells 2021, 10, 3423. https://doi.org/10.3390/cells10123423

​

Cruz CRV, Ferrer JLM and Garcia RL. Concomitant and decoupled effects of cigarette smoke and SCAL1 upregulation on oncogenic phenotypes and ROS detoxification in lung adenocarcinoma cells.  Scientific Reports  (2021) 11:18345.  https://rdcu.be/cxOnK

 

Danac J.M.C. and Garcia R.L. CircPVT1 attenuates negative regulation of NRAS by let-7 and drives cancer cells towards oncogenicity. Scientific Reports  (2021) 11:9021. https://rdcu.be/cjvnt

 

Danac JM, Uy AG and Garcia RL. Exosomal microRNAs in colorectal cancer: Overcoming barriers of the metastatic cascade (Review). Int J Mol Med 47: 112, 2021. https://doi.org/10.3892/ijmm.2021.4945

 

Sacdalan DL, Garcia RL, Diwa MH, Sacdalan DB. Clinicopathologic Factors Associated with Mismatch Repair Status Among Filipino Patients with Young-Onset Colorectal Cancer. Cancer Manag Res. 2021;13:2105-2115
https://doi.org/10.2147/CMAR.S286618

 

Yu, R.T.D., and Garcia, R.L. NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes. Scientific Reports  (2020) 10:11028. https://doi.org/10.1038/s41598-020-67796-8

​

Ghodsinia A.A., Lego J.-A.M.T. and Garcia, R.L. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants. Cells 2020, 9, 1116.                           https://doi.org/10.3390/cells9051116

​

Roquid K.A.R., Alcantara K.M.M and Garcia R.L. (2020). Identification and validation of mRNA 3'untranslated regions of DNMT3B and TET3 as novel competing endogenous RNAs of the tumor suppressor PTEN. Int J. Oncol 56: 544-558. https://doi.org/10.3892/ijo.2019.4947

​

Gibbons J.A., Garcia R.L., Craig PA, Yu G.F.B., Macaulay J.O. (2020). Laboratory classes in biochemistry and molecular biology: A parallel session at the IUBMB/PSBMB 2019 “Harnessing Interdisciplinary Education in Biochemistry and Molecular Biology” conference. Biochem Mol Biol Educ.1–4. https://doi.org/10.1002/bmb.21436 

​

Alcantara K.M.M., Malapit J.R.P., Yu R.T.D,; Garrido J.A.M.G., Rigor J.P.T., Angeles A.K.J., Cutiongco-de la Paz E.M. and Garcia R.L. (2019). Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants. Cells, 8, 1557.  https://doi.org/10.3390/cells8121557

​

Alcantara K.M and Garcia R. (2019). MicroRNA-92a promotes cell proliferation, migration, and survival by directly targeting the tumor suppressor gene NF2 in colorectal and lung cancer cells. Oncology Reports 41: 2103-2106. https://doi.org/10.3892/or.2019.7020

​

Angeles A.K.J., Yu R.T., Cutiongco-de la Paz E.M. and Garcia R. (2019). Phenotypic characterization of the novel, non-hotspot oncogenic KRAS mutants E31D and E63K. Oncology Letters 18: 420-432. https://doi.org/10.3892/ol.2019.10325

​

Algodon S.M., Qui M.D., Estuart A. and Garcia R. (2019). SNPs in MEG3 lncRNA affect its tumor suppressive function via increased proliferative capacity and resistance to apoptosis. FEBS Open Bio 9: P-23-004. DOI:10.1002/2211-5463.12675

​

Uy A.G. and Garcia R. (2019). KRAS status-dependent sorting of lung cancer-associated long noncoding RNAs (lncRNAs) in exosomes released by A549 lung adenocarcinoma cells. FEBS Open Bio 9: P-35-129. DOI:10.1002/2211-5463.12675

​

Viola M.I. and Garcia R. (2019). The functional pseudogene INGX promotes cell cycle progression, survival and migration in HCT116 colorectal cancer cells. FEBS Open Bio 9: ShT-23-3. DOI:10.1002/2211-5463.12674

​

Bataclan C.C., Manongdo M.A., Martija A.A., Ong T., Roquid K.A. and Garcia R. (2018). Confirmatory and Orthogonal Assays for Eliminating Artefactual Drug Bioactivities. FEBS Open Bio 8: P.09-212. DOI: 10.1002/2211-5463.12453

​

Algodon S.M., Amor E.C., Cortez A.T., Garcia R.L., Salvador-Reyes, L.A., Tun J., and Concepcion G.P.  (2019). Tuklas Lunas® Protocols for Drug Discovery and Development Manual 2A: Safety Tests. Publisher: Philippine Council for Health Research and Development. Editors: Amelia Guevara and Rita Alvero. ISBN: 978-971-8662-37-3

​

Allanigue E.J., Amor E.C., Arguilla E., Bataclan C.C., Fabian M.C.P., Fernandez P.L., Garcia R.L., Hernandez C.C.,  Manongdo M.A., Martija A.A., Naing M.D., Ong T.T., Opog A.C., Perez Y.P., Tutor J., Yerro J. Z., Salvador-Reyes L.A., Tun J. and Concepcion G.P.  (2019). Tuklas Lunas® Protocols for Drug Discovery and Development Manual 2B: Primary Bioactivity Assays. Publisher: Philippine Council for Health Research and Development. Editors: Amelia Guevara and Rita Alvero. ISBN: 978-971-8662-38-0

​

Bataclan C.C., Garcia R.L., Manongdo M.A., Martija A.A., Ong T., Yu R.T., Salvador-Reyes L.A., Tun J. and Concepcion G.P. (2019). Tuklas Lunas® Protocols for Drug Discovery and Development Manual 2C: Orthogonal and Secondary Bioactivity Assays.  Publisher: Philippine Council for Health Research and Development. Editors: Amelia Guevara and Rita Alvero. ISBN: 978-971-8662-39-7